Burger R L, Schneider R J, Mehlman C S, Allen R H
J Biol Chem. 1975 Oct 10;250(19):7707-13.
The normal human granulocyte vitamin B12-binding protein, transcobalamin I, and transcobalamin III, have been labeled with 125I-labeled N-succinimidyl 3-(4-hydroxyphenyl)propionate and utilized for plasma clearance studies performed with rabbits. Both moieties of 125I-labeled granulocyte vitamin B12-binding protein-[57Co]vitamin B12 were cleared rapidly from the plasma (is less than 90% by 5 min) by the liver. After 30 min, the bulk of the 125I reappeared in the plasma in small molecular weight (less than 1000) form and was rapidly excreted in the urine. After 60 min the bulk of the [57Co]vitamin B12 reappeared in the plasma bound to rabbit transcobalamin II and was subsequently taken up by a variety of tissues. Approximately 15% of the 125I-labeled granulocyte vitamin B12-binding protein-[57Co-a1vitamin B12 was excreted intact into the bile during the period from 10 to 80 min after injection. The hepatic uptake of the protein-vitamin B12 complex was blocked by the prior injection of desialyzed fetuin but not by native fetuin. Similar results were obtained with 125I-labeled transcobalamin III-[57Co]vitamin B12. Approximately 90% of both moieties of 125I-labeled transcobalamin I-[57Co]vitamin B12 had prolonged plasma survivals similar to that of 125I-labeled bovine serum albumin. After treatment with neuraminadase, both moieties of the 125I-labeled transcobalamin I-[57Co]vitamin B12 complex were cleared rapidly from the plasma by the liver in a manner that was indistinguishable from that observed in the case of untreated granulocyte vitamin B12-binding protein and transcobalamin III. These observations indicate that desialyzed transcobalamin I and the native forms of the granulocyte vitamin B12-binding protein and transcobalamin III are cleared from plasma by the mechanism elucidated by Ashwell and Morell (Ashwell, G., and Morell A. G. (1974) Adv. Enzymol. 41, 99-128) that is capable of clearing a wide variety of asialoglycoproteins. These observations have implications concerning the function of the human R-type vitamin B12-binding proteins, the nature of the enterohepatic circulation of vitamin B12, the biological significance of the mechanism described by Ashwell and Morell, and the etiology of the increased plasma concentration of human R-type protein that occurs frequently in chronic myelogenous leukemia and occasionally in hepatocellular carcinoma and other solid tumors.
正常人粒细胞维生素B12结合蛋白、转钴胺素I和转钴胺素III,已用125I标记的N-琥珀酰亚胺基3-(4-羟苯基)丙酸进行标记,并用于对兔子进行的血浆清除研究。125I标记的粒细胞维生素B12结合蛋白-[57Co]维生素B12的两个部分都被肝脏迅速从血浆中清除(5分钟内清除率小于90%)。30分钟后,大部分125I以小分子质量(小于1000)的形式重新出现在血浆中,并迅速经尿液排出。60分钟后,大部分[57Co]维生素B12重新出现在与兔转钴胺素II结合的血浆中,随后被多种组织摄取。在注射后10至80分钟期间,约15%的125I标记的粒细胞维生素B12结合蛋白-[57Co]维生素B12完整地排入胆汁。预先注射去唾液酸胎球蛋白可阻断蛋白质-维生素B12复合物的肝脏摄取,但天然胎球蛋白则无此作用。用125I标记的转钴胺素III-[57Co]维生素B12也得到了类似结果。125I标记的转钴胺素I-[57Co]维生素B12的两个部分约90%在血浆中的存活时间延长,类似于125I标记的牛血清白蛋白。用神经氨酸酶处理后,125I标记的转钴胺素I-[57Co]维生素B12复合物的两个部分都被肝脏迅速从血浆中清除,其方式与未处理的粒细胞维生素B12结合蛋白和转钴胺素III的情况无法区分。这些观察结果表明,去唾液酸转钴胺素I以及粒细胞维生素B12结合蛋白和转钴胺素III的天然形式通过阿什韦尔和莫雷尔阐明的机制(阿什韦尔,G.,和莫雷尔,A.G.(1974年)《酶学进展》41,99 - 128)从血浆中清除,该机制能够清除多种去唾液酸糖蛋白。这些观察结果对人类R型维生素B12结合蛋白的功能、维生素B12肝肠循环的性质、阿什韦尔和莫雷尔描述的机制的生物学意义以及慢性粒细胞白血病中经常出现且偶尔在肝细胞癌和其他实体瘤中出现的人类R型蛋白血浆浓度升高的病因学具有重要意义。